Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

DREAM

Financiado

The pharmaco-microbiomics of depression

This interdisciplinary project aims to improve response to depression treatment using the gut microbiota. About one third of patients with depression do not respond to treatment with Selective-Serotonin-Reuptake-Inhibitors (SSRIs)... ver más

28/02/2026

GUF

217K€

Presupuesto del proyecto: 217K€

Líder del proyecto

JOHANN WOLFGANG GOETHEUNIVERSITAET FRANKFURT... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 3 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-08-09

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

HORIZON-MSCA-2021-PF-01-01: MSCA Postdoctoral Fellowships 2021

I+D

Cerrada hace 3 años

0% 100% 100%

3 Participantes

GUF

217.31K€ | Lider

Winclove Holding

N.D. | Participante

Proyectos interesantes

gutMAP Gut microbiome-mediated activities of psychotropic drugs 1M€ Cerrado

CNS2023-144218 Fisiopatología de órganos y sistemas 200K€ Cerrado

PID2021-126468OA-I00 INVESTIGACION DE LA INTERACCION ORAL-INTESTINAL-CEREBRAL EN... 97K€ Cerrado

FASTer Identifying the Fast-acting Antidepressant Signatures of Tre... 2M€ Cerrado

PID2021-125428OB-I00 TRASTORNOS DE LA MEMORIA, ANSIEDAD Y DEPRESION INDUCIDOS POR... 206K€ Cerrado

MicroBED The Influence of Gut Microbiota and Microbial Metabolites on... 201K€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 42 meses Fecha Inicio: 2022-08-09
Fecha Fin: 2026-02-28

Presupuesto del proyecto 217K€

Descripción del proyecto This interdisciplinary project aims to improve response to depression treatment using the gut microbiota. About one third of patients with depression do not respond to treatment with Selective-Serotonin-Reuptake-Inhibitors (SSRIs). Moreover, side effects such as gastrointestinal complaints are common. The commensal gut microbiota, residing in the human intestinal tract in trillions, likely contribute to variation in treatment efficacy. This makes them a promising candidate to improve treatment response. The highly inter-individual variable gut bacteria collectively represent an enormous amount of genes, enzymes and transporters (outnumbering human genes by 10-100 times). Hereby, the gut microbiota are involved in processing of orally ingested compounds, and, through the communication highway called the gut-brain-axis, interact with the central nervous system. Anti-depressant medication such as SSRIs reduce gut microbial diversity and change community dynamics. For example, in vitro studies have shown unintentional effects of SSRIs in the gut on a bacterium with a human-analogous serotonin transporter. This negatively affects serotonin metabolism in the gut, potentially contributing to side effects and reduced treatment response. Other similar mechanisms may occur, yet very limited experimental experimental data exist mapping which and how gut microbiota are impacted by SSRIs. Moreover, hardly any studies link SSRI medication induced gut microbial effects to treatment response. Using clinical cohorts, I will dissociate gut microbial profiles of patients responding versus not responding to their SSRI medication. In a culturing experiment, fecal material of such responders and non-responders will be characterized in terms of growth profile after SSRI exposure, transcriptomic and metabolomics. Using these results, a probiotics product will be developed. This project contains clinical, microbial and applied work with great societal and economic potential.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores